Imaging of enzyme replacement therapy using PET
- 15 June 2010
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (24) , 10842-10847
Abstract
Direct enzyme replacement therapy (ERT) has been introduced as a means to treat a number of rare, complex genetic conditions associated with lysosomal dysfunction. Gaucher disease was the first for which this therapy was applied and remains the prototypical example. Although ERT using recombinant lysosomal enzymes has been shown to be effective in altering the clinical course of Gaucher disease, Fabry disease, Hurler syndrome, Hunter syndrome, Maroteaux-Lamy syndrome, and Pompe disease, the recalcitrance of certain disease manifestations underscores important unanswered questions related to dosing regimes, tissue half-life of the recombinant enzyme and the ability of intravenously administered enzyme to reach critical sites of known disease pathology. We have developed an innovative method for tagging acid β-glucocerebrosidase (GCase), the recombinant enzyme formulated in Cerezyme® used to treat Gaucher disease, using an 18 F-labeled substrate analogue that becomes trapped within the active site of the enzyme. Using micro-PET we show that the tissue distribution of injected enzyme can be imaged in a murine model and that the PET data correlate with tissue 18 F counts. Further we show that PET imaging readily monitors pharmacokinetic changes effected by receptor blocking. The ability to 18 F-label GCase to monitor the enzyme distribution and tissue half-life in vivo by PET provides a powerful research tool with an immediate clinical application to Gaucher disease and a clear path for application to other ERTs.Keywords
This publication has 34 references indexed in Scilit:
- Acid β-glucosidase: insights from structural analysis and relevance to Gaucher disease therapyBiological Chemistry, 2008
- Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher diseaseMolecular Genetics and Metabolism, 2008
- Treatment of Lysosomal Storage DisordersDrugs, 2007
- The Role of Mannosylated Enzyme and the Mannose Receptor in Enzyme Replacement TherapyThe American Journal of Human Genetics, 2005
- Synthesis of 2,6‐dideoxy‐2‐fluoro‐6‐[18F]‐fluoro‐β‐D‐glucopyranosyl fluoride (2,6FGF) as a potential imaging probe for glucocerebrosidaseJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- Single Step Stereoselective Synthesis of Unprotected 2,4-Dinitrophenyl GlycosidesTetrahedron Letters, 1995
- Synthesis of 2‐deoxy‐2‐[18F]‐fluoro‐β‐mannosyl [18F]‐fluoride as a potential imaging probe for GlycosidasesJournal of Labelled Compounds and Radiopharmaceuticals, 1992
- The base-catalysed anomerization of dinitrophenyl glycosides: evidence for a novel reaction mechanismCanadian Journal of Chemistry, 1990
- Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: Characterization and evidence for receptor recyclingCell, 1980
- The use of the 2,4‐dinitrophenyl group in sugar chemistry re‐examinedRecueil des Travaux Chimiques des Pays-Bas, 1980